Notably, differences in the ROR values among different drugs further highlight the mechanistic nuances: canakinumab, a selective IL-1β neutralizer, reported data on pneumonia with an ROR of 2.3 (95% CI: 2.07–2.56), whereas neither anakinra nor rilonacept reported an ROR for this event. The gene discussed is IL1B; the disease is susceptibility to pneumonia measurement.